Epidemiological and economic efficiencies of immunization with the commercial influenza

Objective. To estimate the epidemiological and economic efficiencies of using the commercial vaccine Grippol® plus in the able-bodied adult population. Subjects and methods. The investigation was conducted at the Kamensk Uralsky metallurgical works, Sverdlovsk Region, during the 2010-2011 preseasonal and seasonal influenza incidence rises. It enrolled 2400 people who were divided into 2 groups: a study group (n = 1200) and a control one (n = 1200). Epidemiological, laboratory and statistical studies were used to analyze results. Results. In the study group, the incidence rate of influenza with regard to the serological verification of its diagnosis was significantly lower than that in the control group. The efficiency index for Grippol® plus vaccine was 2.15; its efficiency coefficient was 53.5%. Economic costs were 18563.74 and 14739.33 rubles per patient in the control and study groups, respectively. The economic efficiency of Grippol plus vaccine was 2129175.41 rubles or 5.8 rubles per invested ruble. Conclusion. The investigation showed the epidemiological and economic efficiencies of using the commercial vaccine Grippol® plus in the able-bodied adult population.

influenza, vaccination, adult population, epidemiological efficiency, economic efficiency, Grippol® plus